Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07572006 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
A Phase 1 study, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 280
- Enrollment target
NCT07572006: Recruiting Phase 1 study, sponsored by Janssen Research & Development.
NCT07572006 is a Phase 1 study that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 280 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (367% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07572006, a Phase 1 study, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 280 participants
- Enrollment target
Study Summary
The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \[RP2D\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone and/or when administered in addition to standard of care (SoC) therapy at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system). For US sites: The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \[RP2D\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system).
Primary Outcome
DLT is defined as any toxicity that requires discontinuation of treatment; any toxicity resulting in dose reduction of study treatment, any toxicity resulting in a participant receiving less than (\<) 2/3 of their intended dose; any grade 5 toxicity; non-hematologic toxicity (grade 3 or 4); and unacceptable hematologic toxicity.
Interventions
- DRUG JNJ-95804306
- DRUG AML SoC
- DRUG CLL/SLL SoC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2026-05-13 |
| Est. Completion | 2032-09-24 |
| Phase | Phase 1 |
What NCT07572006 shows while recruiting
NCT07572006 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (367% higher).
The record links to 0 conditions, and to 3 interventions - of which JNJ-95804306 is the first listed.
NCT07572006 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07572006 about?
NCT07572006 is a clinical study titled "A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies". The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \[RP2D\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine th...
What is the current status of trial NCT07572006?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2026-05-13. Estimated completion is 2032-09-24.
What interventions are being tested in trial NCT07572006?
The interventions under investigation include: JNJ-95804306 (DRUG), AML SoC (DRUG), CLL/SLL SoC (DRUG).
Who is sponsoring clinical trial NCT07572006?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07572006's enrollment target sits among peer trials
280 141st of 2000 higher than 1,855 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI